Form 4: Hologic Executive Granted 13,458 RSUs

Hologic Inc.'s President of Breast & Skeletal, Mark W. Horvath, was granted 13,458 restricted stock units vesting over three years.

Summary

• Mark W. Horvath, President, Breast & Skeletal for Hologic Inc. (HOLX), was granted 13,458 restricted stock units (RSUs).
• The grant date for these RSUs is November 10, 2025.
• These RSUs will vest in equal installments on each of the first three anniversaries of the grant date.
• Restricted stock units are settled on a one-for-one basis into shares of common stock.
• Following this transaction, Mr. Horvath beneficially owns 23,139 shares directly, which includes 4,605 performance stock units/restricted stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a key executive is generally a positive signal for executive retention and alignment with shareholder interests, reflecting ongoing compensation practices.

Positives

• The grant of restricted stock units aligns executive interests with long-term shareholder value.
• The vesting schedule over three years promotes executive retention and commitment to the company's future performance.

Future Outlook

The restricted stock units granted to Mark W. Horvath are scheduled to vest in equal installments on each of the first three anniversaries of the November 10, 2025 grant date, indicating a future commitment and retention strategy.

Industry Context

This RSU grant is a standard component of executive compensation packages in the medical technology and diagnostics industry, designed to incentivize long-term performance and align management interests with shareholder returns.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with long-term company performance.
• Employees: No direct impact on general employees, but reflects standard executive compensation practices.

Next Steps

• First vesting installment of the 13,458 restricted stock units on November 10, 2026.
• Second vesting installment of the 13,458 restricted stock units on November 10, 2027.
• Third and final vesting installment of the 13,458 restricted stock units on November 10, 2028.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of restricted stock units to a key executive, which is a standard component of compensation designed to align management incentives with long-term shareholder value. It does not present new information that would fundamentally alter the investment thesis for Hologic Inc., thus a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals.

Keywords

Hologic Inc., HOLX, Restricted Stock Units, RSU Grant, Executive Compensation, Insider Transaction, Form 4, Mark W. Horvath, Equity Award